EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Liposome Encapsulation Enhances Ripasudil Therapeutic Efficacy Against Proliferative Vitreoretinal Diseases: Implications in Advanced Ocular Treatment

Rui Ji, Keijiro Ishikawa, Wei Tan, Kenichiro Mori, Ryotaro Tsukamoto, Naoya Matsunaga, Kohei Kiyohara, Yosuke Fukuda, Iori Wada, Tomoyuki Isobe, Tomohito Tanihara, Yuya Yoshida and 11 more

Investigative Ophthalmology & Visual Science · 2025-06-17 · 66 (6) · 56

DOI: 10.1167/iovs.66.6.56 ↗

At a glance

Journal article in Investigative Ophthalmology & Visual Science, published on 2025-06-17. Written by Rui Ji and 22 co-authors. Institution: Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Major MEDLINE topics: Vitreoretinopathy, Proliferative, Isoquinolines, Sulfonamides. Cited 5 times so far (Crossref); 68 references. The full text is freely available (open access, CC BY 4.0). Funded by: NEI NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Purpose

Proliferative vitreoretinal diseases, such as proliferative vitreoretinopathy (PVR) and neovascular age-related macular degeneration (nAMD), pose substantial challenges in their advanced stages owing to the development of retinal fibrous membranes. Current therapeutic modalities, including surgical interventions for PVR and antivascular endothelial growth factor therapy for nAMD, cannot effectively manage intraocular fibrosis associated with epithelial-to-mesenchymal transition (EMT) in retinal pigment epithelium (RPE) cells. Through drug screening, we identified ripasudil, a Rho-kinase inhibitor, as a remarkable suppressor of RPE-EMT. However, the short vitreal half-lives of small-molecule drugs, coupled with the limited stability of ripasudil in the ocular environment, impede its application in vitreoretinal diseases. Considering the advances in nanotechnology-assisted improvement in drug stability and cellular uptake as well as controlled release, we aimed to enhance the efficacy of ripasudil through liposome encapsulation.

Methods

After ripasudil encapsulation, we performed comprehensive in vivo and in vitro analyses and pharmacokinetic studies.

Results

Liposome-encapsulated ripasudil (Lipo-Ripa) demonstrated a substantial reduction in subretinal fibrosis in an advanced AMD model and more effective inhibition of PVR progression in rabbits than that induced by ripasudil alone. Pharmacokinetic studies revealed that Lipo-Ripa exhibited improved retention capacity in the vitreous and retina, alongside reduced permeability through the RPE barrier and increased cellular uptake. These characteristics resulted in a sustained elevation of drug concentration within the ocular tissues over time.

Conclusions

Our findings suggest that liposomal encapsulation of ripasudil supports enhanced bioavailability and effectiveness of the drug, presenting a promising innovative therapeutic approach for the treatment of proliferative vitreoretinopathy.

Subjects

MeSH terms (MEDLINE)

Vitreoretinopathy, ProliferativeIsoquinolinesSulfonamidesAnimalsLiposomesRabbitsRetinal Pigment EpitheliumDisease Models, AnimalHumansEpithelial-Mesenchymal TransitionIntravitreal Injections

Substances

LiposomesK-115IsoquinolinesSulfonamides

Authors and institutions

  • Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
  • Tokyo New Drug Research Laboratories, Kowa Company, Ltd., Tokyo, Japan.
  • Department of Drug Discovery Structural Analysis, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
  • DDS Strategy Firm, Tokyo, Japan.
  • Department of Ophthalmology, Juntendo University School of Medicine, Tokyo, Japan.

Funding

  • NEI NIH HHS

Cite

APA

Ji, R., Ishikawa, K., Tan, W., Mori, K., Tsukamoto, R., Matsunaga, N., Kiyohara, K., Fukuda, Y., Wada, I., Isobe, T., Tanihara, T., Yoshida, Y., Mayanagi, K., Oyama, K., Terada, Y., Otsuki, K., Hamamura, K., Kikuchi, H., Nakao, S., …, & Sonoda, K. H. (2025). Liposome Encapsulation Enhances Ripasudil Therapeutic Efficacy Against Proliferative Vitreoretinal Diseases: Implications in Advanced Ocular Treatment. Investigative Ophthalmology & Visual Science, 66(6), 56. https://doi.org/10.1167/iovs.66.6.56

Vancouver

Ji R, Ishikawa K, Tan W, Mori K, Tsukamoto R, Matsunaga N, et al. Liposome Encapsulation Enhances Ripasudil Therapeutic Efficacy Against Proliferative Vitreoretinal Diseases: Implications in Advanced Ocular Treatment. Investigative Ophthalmology & Visual Science. 2025;66(6):56. doi:10.1167/iovs.66.6.56

BibTeX
@article{Ji2025,
  author = {Ji, Rui and Ishikawa, Keijiro and Tan, Wei and Mori, Kenichiro and Tsukamoto, Ryotaro and Matsunaga, Naoya and Kiyohara, Kohei and Fukuda, Yosuke and Wada, Iori and Isobe, Tomoyuki and Tanihara, Tomohito and Yoshida, Yuya and Mayanagi, Kouta and Oyama, Kosuke and Terada, Yuma and Otsuki, Kaita and Hamamura, Kengo and Kikuchi, Hiroshi and Nakao, Shintaro and Yoshida, Shigeo and Kannan, Ram and Ohdo, Shigehiro and Sonoda, Koh-Hei},
  title = {Liposome Encapsulation Enhances Ripasudil Therapeutic Efficacy Against Proliferative Vitreoretinal Diseases: Implications in Advanced Ocular Treatment},
  journal = {Investigative Ophthalmology & Visual Science},
  year = {2025},
  volume = {66},
  number = {6},
  pages = {56},
  doi = {10.1167/iovs.66.6.56}
}
Start for free →